Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF for HBV Prophylaxis in Liver Transplant
NCT04703465Unknown
- Sponsor
- Renji Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of tenofovir alafenamide in hepatitis B (HBV), sponsored by Renji Hospital. Primary endpoint: De novo HBV infected rate after liver transplantation at 48 weeks. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04703465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703465.